No molecular IC50/potency disclosed in ADCdb or PubChem. ADCdb reports clinical efficacy only: objective response rates ranging ~13% to 100% across trials/doses/indications (relapsed/refractory hairy cell leukemia and ALL). Mechanism: PE38 catalyzes ADP-ribosylation of eukaryotic